Novel Temperature Controlled Surface Dissolution of Excipient Particles for Carrier Based Dry Powder Inhaler Formulations
- 1 January 2006
- journal article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 32 (2) , 243-251
- https://doi.org/10.1080/03639040500466395
Abstract
The surface of lactose monohydrate was modified by solution phase variable temperature dissolution. Lactose monohydrate crystals were added to a known volume of a saturated solution of lactose monohydrate at 25 degrees C. The temperature of the mixture was then ramped to either 30, 35, 40, or 50 degrees C to produce lactose monohydrate batches with reduced levels of fines and lower surface roughness. A dramatic decrease in surface roughness with increasing dissolution temperature was visually observed using scanning electron microscopy. Particle size analysis suggested that the level of lactose fines was reduced after treatment at the lowest dissolution temperature, 30 degrees C. Evaluation of the samples' drug aerosolization using a twin stage impinger, after blending with salbutamol sulphate, suggested that even though there were dramatic changes in roughness and particle size distribution after surface dissolution at 30 degrees C, there was no significant difference in aerosolization as measured by fine particle fraction. However, after surface dissolution at 35 degrees C, there was an increase in fine particle fraction. Surface dissolution at even higher temperatures did not result in any further increase in fine particle fraction. These observations suggest that surface roughness and fines play an important role in the aerosolization of salbutamol sulphate, but the inter-relationships are not straightforward.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalersInternational Journal of Pharmaceutics, 2004
- The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalersInternational Journal of Pharmaceutics, 2004
- Functionality testing of inhalation grade lactoseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2004
- Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing”Journal of Pharmacy and Pharmacology, 2002
- Quantification of the Surface Morphologies of Lactose Carriers and Their Effect on the in Vitro Deposition of Salbutamol Sulphate.CHEMICAL & PHARMACEUTICAL BULLETIN, 2000
- Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulationInternational Journal of Pharmaceutics, 1999
- The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitroInternational Journal of Pharmaceutics, 1998
- Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrateInternational Journal of Pharmaceutics, 1998
- In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro depositionInternational Journal of Pharmaceutics, 1997
- The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalersJournal of Pharmacy and Pharmacology, 1987